Advisors Asset Management Inc. boosted its stake in Bristol-Myers Squibb (NYSE: BMY – Get Rating) by 10.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 89,966 shares of the biopharmaceutical company stock after buying an additional 8,755 shares during the period. Advisors Asset Management Inc.’s holdings in Bristol-Myers Squibb were worth $ 5,609,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Stonebridge Capital Advisors LLC boosted its holdings in Bristol-Myers Squibb by 4.8% in the 3rd quarter. Stonebridge Capital Advisors LLC now owns 144,196 shares of the biopharmaceutical company stock valued at $ 8,532,000 after purchasing an additional 6,651 shares during the period. Cubist Systematic Strategies LLC boosted its holdings in Bristol-Myers Squibb by 215.0% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 197,512 shares of the biopharmaceutical company stock valued at $ 11,687,000 after purchasing an additional 134,815 shares during the period. Independence Bank of Kentucky lifted its holdings in shares of Bristol-Myers Squibb by 15.1% during the 4th quarter. Independence Bank of Kentucky now owns 18,439 shares of the biopharmaceutical company stock worth $ 1,150,000 after acquiring an additional 2,425 shares during the period. MML Investors Services LLC lifted its holdings in shares of Bristol-Myers Squibb by 15.8% during the 3rd quarter. MML Investors Services LLC now owns 421,168 shares of the biopharmaceutical company stock worth $ 24,920,000 after acquiring an additional 57,325 shares during the period. Finally, Pinnacle Private Wealth LLC bought a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $ 306,000. 73.07% of the stock is owned by hedge funds and other institutional investors.
In other news, CEO Giovanni Caforio sold 25,000 shares of the stock in a transaction on Monday, March 21st. The shares were sold at an average price of $ 71.52, for a total transaction of $ 1,788,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Rupert Vessey sold 74,559 shares of the stock in a transaction on Wednesday, March 16th. The stock was sold at an average price of $ 69.25, for a total transaction of $ 5,163,210.75. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 164,559 shares of company stock valued at $ 11,819,061. Corporate insiders own 0.09% of the company stock.
Shares of NYSE BMY opened at $ 75.09 on Monday. The company has a debt-to-equity ratio of 1.18, a quick ratio of 1.23 and a current ratio of 1.32. Bristol-Myers Squibb has a 52-week low of $ 53.22 and a 52-week high of $ 78.61. The firm has a 50 day moving average price of $ 76.25 and a two-hundred day moving average price of $ 68.97. The stock has a market cap of $ 159.87 billion, a P / E ratio of 26.63, a price-to-earnings-growth ratio of 1.60 and a beta of 0.49.
Bristol-Myers Squibb (NYSE: BMY – Get Rating) last announced its quarterly earnings results on Friday, April 29th. The biopharmaceutical company reported $ 1.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $ 1.92 by $ 0.04. Bristol-Myers Squibb had a net margin of 13.31% and a return on equity of 48.37%. The firm had revenue of $ 11.65 billion during the quarter, compared to analysts’ expectations of $ 11.34 billion. During the same period in the prior year, the company posted $ 1.74 EPS. The company revenue was up 5.2% on a year-over-year basis. Analysts predict that Bristol-Myers Squibb will post 7.55 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on the stock. Morgan Stanley cut their price target on shares of Bristol-Myers Squibb from $ 66.00 to $ 64.00 and set an “underweight” rating for the company in a report on Wednesday, April 6th. BMO Capital Markets upped their price target on shares of Bristol-Myers Squibb from $ 87.00 to $ 92.00 in a report on Monday, May 2nd. Bank of America upped their price target on shares of Bristol-Myers Squibb from $ 78.00 to $ 80.00 and gave the stock a “buy” rating in a report on Monday, June 6th. StockNews.com assumed coverage on shares of Bristol-Myers Squibb in a report on Thursday, March 31st. They set a “strong-buy” rating for the company. Finally, Citigroup reissued a “buy” rating and issued a $ 90.00 price objective on shares of Bristol-Myers Squibb in a research note on Friday, June 3rd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company stock. According to MarketBeat.com, Bristol-Myers Squibb currently has a consensus rating of “Buy” and an average price target of $ 74.27.
About Bristol-Myers Squibb: (Get Rating)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke / systemic embolism in NVAF, and for the treatment of DVT / PE; Opdivo for anti-cancer indications; Pomalyst / Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.
See Also:
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE: BMY – Get Rating).
Receive News & Ratings for Bristol-Myers Squibb Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.
.